Skip to main content

Will Brexit affect access to medicines?

29th January 2018

Submitted by:

Sara Waddington

Chris Gould, managing director at Active Pharma Ideas Ltd, examines the “Brexit balancing act” between patient access to medicines, industry’s concerns and the complexities facing those undertaking the negotiations.

As recently as November, there were apparently opinions still held by some in the pharmaceutical industry that “Brexit is going to be what it is and we’re not going to worry about it”. While such stoicism has a touch of the Einstein about it (“I never think of the future; it comes soon enough”), it would be worrying if this truly represented preparations for a post-Brexit landscape. It is worth repeating just some of the key areas expected to be impacted: cross-border controls delaying access to medicines, exclusion from EU pharmacovigilance data-sharing (EudraVigilance), reduced later-phase UK clinical trial activity, confusion over product licence reviews and timetabling, increased costs for EU batch release, tariffs, re-classification of the UK as a “third country” for Good Manufacturing Practice (GMP) and second-tier ranking regarding access to new medicines. It is quite a list and something entirely appropriate to be worried about.

The EMA and BEIS Committee

It was perhaps an appropriate coincidence that, also in November, the European Medicines Agency (EMA) issued “Practical Guidance” on the legal consequences for medicinal products following a UK withdrawal from the EU; thirteen critical questions and answers and a further example of value provided by the (UK-based) EMA. It would perhaps not be amiss to survey industry regarding awareness of the guidance and any plans put in place, if nothing else to reassure those relying on access to medicines that a “wait and see” approach was no longer holding sway.

By way of offering some encouragement, industry’s proactivity was in evidence at the House of Commons’ Business, Energy and Industrial Strategy (BEIS) Committee: Leaving the EU: Implications for the Pharmaceutical Industry (December 2017). Key industry representatives included Mike Thompson (chief executive, Association of the British Pharmaceutical Industry (ABPI)); John Smith, (chief executive, Proprietary Association of Great Britain); Paul Fleming, (technical director, British Generic Manufacturers Association) and their clearly-stated overriding concern was “to continue to supply medicines to patients across Europe.” Who would disagree with that? If industry does not have as a paramount concern patient access to medicines (and that means quality, efficacy and pricing as well as availability), then that is certainly something we should all “worry about”.

While evidence to the BEIS Committee demonstrated an industry fully aware of the issues, it was also a fascinating (but at times worrying) insight into an apparent gulf between pharmaceutical industry’s concerns and levels of understanding displayed by the Committee. Whether in Committee members’ apparent misunderstanding that animal testing is not part of batch release testing, or in proposing that production of the UK’s drug requirements be undertaken domestically, or an unawareness of the extent to which drug manufacture has exited the UK, or suggesting lost UK pharmaceutical sales to the EU could be replaced by business to other regions, then it would perhaps not be a surprise were observers to be concerned when it comes down to the specific and detailed Brexit negotiations themselves. Mike Thompson put his finger on it: “Sometimes you can see that the scale of [the] challenge that is facing those who are negotiating arrangements is such that somehow these things could get missed, the officials cannot cope with it”.

Potential impact to consider

To be clear, fundamentally we have a lose-lose situation across Europe. Mike Thompson says “people need to understand that this is not an issue about UK patients versus EU patients. This is about patients across the whole of Europe”. On a monthly basis, 45 million patient packs of medicines produced in Europe and covering approximately 2,200 final products enter the UK while 37 million packs manufactured in the UK (approximately 2,600 final products) are exported to the EU. Consider also UK legal entities and the numbers of EU marketing authorisations they hold: around 400 (approximately 45%) centrally authorised products and almost 6,000 (approximately 10%) covered by decentralised and mutual recognition procedures. Whether in finding ways to remain compliant to current regulations or in adhering to new arrangements, it would be no surprise were the inevitable costs ultimately to be passed on to the public.

"This is not an issue about UK patients versus EU patients. This is about patients across the whole of Europe"

Those in the pharmaceutical industry are well aware that it is the mountain of day-to-day compliance and the myriad of processes, regulations and guidelines that can ultimately dictate the availability of medicines. Therefore, while the BEIS Committee (not unreasonably) is asking whether UK the pharmaceutical industry will remain a centre for innovation or has access to an appropriate talent pool, in fairness, what pre-occupies patients today, and rightly so, is “will I still get my medicines tomorrow?” When the likes of Johnson & Johnson state that tariffs with the EU would make it “extremely challenging … to continue to prioritise the UK in any future supply-chain planning”, no clearer message is needed. The pharmaceutical industry will face an enormous struggle to ensure continued patient access to medicines and, for the moment, getting Brexit negotiators to grasp what is at stake still appears to be part of that effort.

To discuss this article, Chris Gould can be contacted at chrisgould@activepharmaideas.com

AI: How machines learn to ‘see’

How can sheet metal machinery learn to ‘see’ using artificial intelligence (AI)? In the December

Submitted by:

Sara Waddington

"Integrate to innovate"

TIMTOS, a major global smart manufacturing and machine tool exhibition in Taipei (Taiwan), will take

Submitted by:

Sara Waddington

Meeting market challenges

ISMR sat down with Voortman’s Head of Commerce, Rutger Voortman, to discover how Voortman’s philosophy

Submitted by:

Sara Waddington

Rapid process change

Spanish manufacturer, Viñolas Metall, is gearing up for Industry 5.0 with new welding solutions from

Submitted by:

Sara Waddington

The robotics race

We highlight market forecasts, the latest trends and the speed of adoption for industrial robotics

Submitted by:

Sara Waddington

Making waste work

Building sustainability into waste management processes will help metal workshops to survive in challenging times

Submitted by:

Sara Waddington

A sustainable future

In the May 2023 issue of International Sheet Metal Review magazine, we analyse trends, drivers

Submitted by:

Sara Waddington

First 'Made in Germany' MINI

The new, fully electric MINI model generation continues to grow. In 2023, production of the

Submitted by:

Sara Waddington

Geopolitical and economic shocks

The COVID-19 pandemic and Russia-Ukraine war profoundly reorganised global structures and relationships in 2022, and

Submitted by:

Sara Waddington

Closing the loop

Gunnar Groebler, Chairman of the Executive Board of Salzgitter AG, and KHS Managing Director, Kai

Submitted by:

Sara Waddington

A strong focus

In the November 2024 issue of ISMR, Matthias Huber, CEO, RAS Reinhardt Maschinenbau GmbH, outlines

Submitted by:

Sara Waddington

Don’t miss EuroBLECH 2024

Don’t miss the 27th International Sheet Metal Working Technology Exhibition, EuroBLECH 2024, from 22-25 October

Submitted by:

Sara Waddington

An eye on innovation

An eye on innovation

This April’s MACH 2024 trade show in the UK featured live

Submitted by:

Sara Waddington

"Integrate to innovate"

TIMTOS, a major global smart manufacturing and machine tool exhibition in Taipei (Taiwan), will take

Submitted by:

Sara Waddington

A high-level view

In the December 2023/January 2024 issue of ISMR, we highlight trends, drivers, opportunities and challenges

Submitted by:

Sara Waddington

The Gender Gap

To celebrate International Women’s Day on 8 March 2023, the April issue of ISMR features

Submitted by:

Sara Waddington

Geopolitical and economic shocks

The COVID-19 pandemic and Russia-Ukraine war profoundly reorganised global structures and relationships in 2022, and

Submitted by:

Sara Waddington

A design-driven process

Additive manufacturing revolves around the creation of an object by generating one layer at a

Submitted by:

Sara Waddington

Forming the future

Deep drawing is a manufacturing process in which sheet metal is progressively formed into a

Submitted by:

Sara Waddington

Pressing for action

ISMR highlights an alphabetical selection of the latest new global stamping, tooling and pressing innovations

Submitted by:

Sara Waddington

An eye on innovation

An eye on innovation

This April’s MACH 2024 trade show in the UK featured live

Submitted by:

Sara Waddington